Results 101 to 110 of about 3,776 (143)

Talimogene laherparepvec resulting in near-complete response in a patient with treatment-refractory Merkel cell carcinoma. [PDF]

Australas J Dermatol, 2022
Cilento MA, Klein O, Egan E, Roberts-Thomson R.   +3 more
europepmc   +1 more source

Oncolytic viral kinetics mechanistic modeling of Talimogene Laherparepvec (T-VEC) a first-in-class oncolytic viral therapy in patients with advanced melanoma. [PDF]

CPT Pharmacometrics Syst Pharmacol, 2023
Ahamadi M, Kast J, Chen PW, Huang X, Dutta S, Upreti VV.   +5 more
europepmc   +1 more source

Inflammatory melanoma in transit metastases with complete response to talimogene laherparepvec

JAAD Case Reports, 2017
Jonathan T. Blackmon, Michael S. Stratton, MD, Young Kwak, MD, Peter G. Pavlidakey, MD, Andrzej T. Slominski, MD, Svetlana B. McKee, RN, BSN, Toni M. Viator, RN, Ju Young Kim, PhD, Conway C. Huang, MD, Robert M. Conry, MD   +9 more
doaj   +1 more source

Talimogene laherparepvec induced bullous pemphigoid. [PDF]

JAAD Case Rep
Davoudi S, Mahmoud F, Abbott J.
europepmc   +1 more source

Increased risk of cutaneous immune-related adverse events in patients treated with talimogene laherparepvec and immune checkpoint inhibitors: A multi-hospital cohort study. [PDF]

J Am Acad Dermatol, 2023
Leung BW, Wan G, Nguyen N, Rashdan H, Zhang S, Chen W, Cohen S, Boland GM, Sullivan RJ, Fadden RM, Kaufman HL, Kwatra SG, LeBoeuf NR, Semenov YR.   +13 more
europepmc   +1 more source

Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO). [PDF]

Nat Commun
Pascual T, Vidal M, Cejalvo JM, Vega E, Sanfeliu E, Villacampa G, Ganau S, Parreño AMJ, Zamora E, Miranda I, Delgado A, Bermejo B, Seguí E, Brasó-Maristanty F, de la Cruz-Merino L, Juan M, Galván P, Gonzàlez-Farré X, Chillara S, Villagrasa P, Pfefferle AD, O'Connell CE, Ferrero-Cafiero JM, Oliveira M, Perou CM, Prat A.   +25 more
europepmc   +1 more source

A phase 1, first-in-child, multicenter study to evaluate the safety and efficacy of the oncolytic herpes virus talimogene laherparepvec in pediatric patients with advanced solid tumors. [PDF]

Front Pediatr, 2023
Moreno L, Teira P, Croop JM, Gerber NU, André N, Aerts I, Gros Subias L, De Wilde B, Bautista F, Turpin B, Kunduri S, Hamidi A, Lawrence T, Streby KA.   +13 more
europepmc   +1 more source

Intralesional Talimogene Laherparepvec Immunotherapy for Melanoma: A Case Study. [PDF]

Cureus
Ghebrehiwet M, Pavlis J, Gomez-Meade C.
europepmc   +1 more source

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma. [PDF]

J Clin Oncol, 2023
Chesney JA, Ribas A, Long GV, Kirkwood JM, Dummer R, Puzanov I, Hoeller C, Gajewski TF, Gutzmer R, Rutkowski P, Demidov L, Arenberger P, Shin SJ, Ferrucci PF, Haydon A, Hyngstrom J, van Thienen JV, Haferkamp S, Guilera JM, Rapoport BL, VanderWalde A, Diede SJ, Anderson JR, Treichel S, Chan EL, Bhatta S, Gansert J, Hodi FS, Gogas H.   +28 more
europepmc   +1 more source

Clinical Improvement of Treatment-Resistant Metastatic Basal Cell Carcinoma After Intratumoral Injection of Talimogene Laherparepvec. [PDF]

Dermatol Surg
Che Y, Abou-Taleb F, Reddy SA, Chang ALS.   +3 more
europepmc   +1 more source